Advertisement

Topics

Biotech Targeting Alzheimer's Disease Advances Toward Phase 1

02:00 EDT 13 Jun 2018 | InvestorIdeas

June 13, 2018 (Investorideas.com Newswire) Having secured a manufacturing partner for its proprietary antibody candidate, this precision medicine company charts progress toward a Phase 1 trial in Alzheimer's disease.

Original Article: Biotech Targeting Alzheimer's Disease Advances Toward Phase 1

NEXT ARTICLE

More From BioPortfolio on "Biotech Targeting Alzheimer's Disease Advances Toward Phase 1"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...